Form 4: Xeris Biopharma Holdings Executive Beth Hecht Reports Stock Transaction

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, reports the withholding of shares to cover tax obligations and acquisition of shares through the employee stock purchase plan.

Summary

• On January 3, 2025, Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, had 32,039 shares withheld to cover income tax obligations related to the vesting of Restricted Stock Units.
• The shares were withheld at a price of $3.61.
• Following the transaction, Hecht beneficially owns 1,352,794 shares of common stock.
• This total includes 4,031 shares acquired on December 31, 2024, under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to tax obligations and employee benefits, with no indication of significant positive or negative developments.

Positives

• The acquisition of 4,031 shares through the employee stock purchase plan indicates confidence in the company's future.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of insider transactions. This filing indicates transactions by a company insider, which are closely watched by investors.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve a relatively small number of shares compared to the total outstanding.

Key Dates